Botulinum Toxin Type A in the Treatment of Chronic Migraine Without Medication Overuse

Keywords

Migraine, Medicine, Placebo, Botulinum toxin, Chronic Migraine

References

• Chronic Daily HeadacheStephen D. Silberstein — 2003
• Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled StudyDavid W. Dodick, Alexander Mauskop, Arthur H. Elkind — 2005
• Classification of daily and near-daily headachesStephen D. Silberstein, Richard B. Lipton, Martin J. Sliwinski — 1996
• Classification of Daily and Near‐Daily Headaches: Proposed Revisions to the IHS CriteriaStephen D. Silberstein, Richard B. Lipton, Seymour Solomon — 1994
• Migraine: Epidemiology, Impact, and Risk Factors for ProgressionRichard B. Lipton, Marcelo E. Bigal — 2005
• The International Classification of Headache DisordersJes Olesen — 2008
• Serotonin, the Cerebellum, and AtaxiaSudhansu Chokroverty — 1994
• A Report on the Journal 2004Peter J. Goadsby — 2004
• Analgesic overuse among subjects with headache, neck, and low-back painJ.‐A. Zwart, Grete Dyb, K. Hagen — 2004
• Features of medication overuse headache following overuse of different acute headache drugsVolker Limmroth, Zaza Katsarava, G. Fritsche — 2002
• The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—-Revision of Criteria for 8.2 Medication-Overuse HeadacheSD Silberstein, Jes Olesen, M.G. Bousser — 2005
• Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled TrialNinan T. Mathew, Benjamin Frishberg, Marek Gawel — 2005
• Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.Stephen D. Silberstein, Stuart R. Stark, Sylvia Lucas — 2005
• Management of Chronic Daily Headache: Challenges in Clinical PracticeJoel R. Saper, David W. Dodick, Jonathan P. Gladstone — 2005
• Preventing chronicity of migraineM Fanciullacci, Francesco De Cesaris — 2005
• Is migraine a progressive brain disease?Richard B. Lipton — 2004
• When migraine progresses: transformed or chronic migraineMarcelo E. Bigal, Richard B. Lipton — 2006
• Incidence and predictors for chronicity of headache in patients with episodic migraineZaza Katsarava, Sebastian Schneeweiß, Tobias Kurth — 2004
• Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review)Stephen D. Silberstein — 2000
• The Eighth Headache Symposium March 27, 1993Stephen D. Silberstein — 1994

Cited by

• Klassifikation und Therapie des Medikamenten-Übergebrauch-Kopfschmerzes (MÜK)Hartmut Göbel, Katja Heinze‐Kuhn, Irene Petersen — 2014
• Are the current IHS guidelines for migraine drug trials being followed?Leopoldo Tolívar Alas — 2010
• Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.佐栄子 広田, 智之 久保田, 倫洋 藤井 — 2017
• OnabotulinumtoxinA en la migraña crónica: de la teoría de los ensayos clínicos a la práctica clínicaRogelio Leira Muiño — 2014
• Therapie und Versorgung bei chronischer MigräneAndreas Straube, Charly Gaul, Stefanie Förderreuther — 2012
• Re-Engineering Clostridial Neurotoxins for the Treatment of Chronic PainAndy Pickett — 2010
• Onabotulinumtoxin A en el tratamiento de la migraña crónicaJosé Miguel Láinez Andrés — 2012
• Botulinum neurotoxin in the treatment of headache disorders.Alexander Mauskop — 2010
• Botulinum neurotoxin: Progress in negating its neurotoxicity; and in extending its therapeutic utility via molecular engineering. MiniReview.Richard M. Kostrzewa, Rose Anna Kostrzewa, John P. Kostrzewa — 2015
• Estudi de les diferències psicopatològiques en pacients amb mal de cap crònic, episòdic i control. Relació amb la resposta al tractamentIsabel Sala — 2010
• Treatment of Chronic Migraine with Focus on Botulinum NeurotoxinsSara M. Schaefer, Christopher Gottschalk, Bahman Jabbari — 2015
• Patient reported effic acy of the use of Botulinum toxin type A in the treatment of chronic migraine headachesPatrick F. Whitney — 2010
• Treatment of refractory pain with botulinum toxins--an evidence-based review.Bahman Jabbari, Duarte Machado — 2011
• OnabotulinumtoxinA for chronic migraine: a critical appraisalFayyaz Ahmed, Rubesh Gooriah — 2015
• Therapeutic use of botulinum toxin in migraine: mechanisms of actionRoshni Ramachandran, Tony L. Yaksh — 2014
• Abstracts and Citations: July 2010Stephen H. Landy, Robert G. Kaniecki, Frederick R. Taylor — 2010
• Botulinum toxin in the treatment of post-traumatic headache - case study.Marcela Lippert-Grüner — 2012
• Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: A retrospective studyKuan-Hsiang Lin, Shih‐Pin Chen, Jong‐Ling Fuh — 2014
• Recent advancements in anti-migraine drug research: focus on attempts to decrease neuronal hyperexcitability.Hedvig Bölcskei, Bence Farkas, Pál Kocsis — 2009
• OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical ProgramSheena K. Aurora, Paul Winner, Marshall C. Freeman — 2011

Related papers

• Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and PreventionRichard B. Lipton, Stephen D. Silberstein — 2015
• Field Testing Alternative Criteria for Chronic MigraineME Bigal, SJ Tepper, FD Sheftell — 2006
• Hypersensitivity to calcitonin gene-related peptide in chronic migraineAfrim Iljazi, Håkan Ashina, Zixuan Alice Zhuang — 2020
• The Face of Chronic Migraine Which Has Started to be Clarified.Zeynep Aydın Özemir, Betül Baykan — 2013
• Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidenceModar Khalil, David Moreno‐Ajona, Maria Dolores Villar‐Martínez — 2022
• Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) StudyDawn C. Buse, Kristina M. Fanning, Michael L. Reed — 2019
• Chronic migraine is an earlier stage of transformed migraine in adultsME Bigal, Alan M. Rapoport, FD Sheftell — 2005
• Calcitonin gene-related peptide (CGRP) concentrations outside migraine attacks in peripheral blood as a potential biomarker for chronic migraineShowkat hassan Bhat, Ravouf Asimi, Zafar A. Shah — 2023
• When migraine progresses: transformed or chronic migraineMarcelo E. Bigal, Richard B. Lipton — 2006
• Safety and efficacy of botulinum toxin a in MS patients with intractable chronic migraineAbolfazl Eftekhari, Sasan Kazemian, Seyedfakhreddin Nabavi — 2017